Loading…
Loading…
CNBX does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CNBX and 80,000+ other tickers.
See exactly how CNBX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNBX and 80,000+ other tickers.
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended…
CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 100,000 shares, a growth of 102.6% from the December 31st total of 49,357 shares. Based on an average daily trading volume, of 73,481,118 shares, the short-interest
CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 49,357 shares, a decrease of 97.5% from the December 15th total of 1,939,991 shares. Based on an average daily trading volume, of 27,586,017
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19 th.
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients. These patent applications are now part of the Cannabics growing IP portfolio comprising of eight patent families with five granted patents and 19 pending applications.
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.